Pharma News
-
![More generics consolidation coming? Novartis deal rumors point up the industry's]( "More generics consolidation coming? Novartis deal rumors point up the industry's")
More generics consolidation coming? Novartis deal rumors point up the industry's
2017-04-01If Novartis does snap up Amneal to beef up its own Sandoz unit, the deal will say as much about the state of the generics industry as it does about Novartis.
-
![Corbus’ anabasum meets safety and tolerability goals in cystic fibrosis study]( "Corbus’ anabasum meets safety and tolerability goals in cystic fibrosis study")
Corbus’ anabasum meets safety and tolerability goals in cystic fibrosis study
2017-04-01A phase 2 trial evaluating Corbus Pharmaceuticals’ multiple doses of anabasum (Resunab) has met its primary objective in patients with cystic fibrosis, demonstrating an acceptable safety and tolerability profile with no severe adverse events.
-
-
Pharmaceutical Industry Overview
The magazine has been officially published in August 2024 and will be distributed at CPHI Korea 2024 and CPHI Milan 2024. It could be permanently available for download online. We sincerely invite you to join us in the publicity, making full use of the influence of the journal to promote your brand & products, expand your corporate influence in the global market.Published in: Aug. 2024
Hot News
-
Top 10 Global CDMO Rankings in 2022
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Forecast of TOP 10 global best-selling drugs in 2021
-
Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Top 30 best-selling oncology drugs in the world in 2020
-
Breaking News! China's First KRAS G12D Inhibitor Approved for Clinical Use
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
